The recent rotation into healthcare stocks and out of hot technology plays can be epitomized by the strong outperformance of Eli Lilly shares relative to Nvidia’s stock. Since the tech sector peaked ...

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Furthermore, Novo Nordisk is anticipating ...

My sisters and I had an annual tradition as children. Every Christmas Eve, after donning our new Christmas pajamas and posing for a dim photo on the stairs in our house, we’d retreat to my oldest ...

The obesity and diabetes drug boom is no longer a one-cycle story. Demand for GLP-1 treatments continues to exceed supply, with physicians expanding use beyond diabetes into weight management and ...

Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s ...

South Carolina men’s basketball was short-handed for its rivalry matchup against Clemson on Tuesday. USC freshman guard Eli Ellis was out for Tuesday’s 68-61 loss against the Tigers with a left ankle ...

Vanderbilt football will be without the top tight end in the country, Eli Stowers, when the No. 12 Commodores close out their season at the ReliaQuest Bowl. Stowers, who received the 2025 John Mackey ...

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 31.02% on an annualized basis producing an average annual return of 44.05%. Currently, Eli Lilly has a market capitalization ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by Eli Lilly could offer an intriguing off-ramp. On Thursday morning, Eli ...

Eli Lilly's recent long streak of correction for nine trading days calls for a look at the stock even as it has stabilised now. It's explained by stretched valuations and also the lowering of prices ...

Dec 17 (Reuters) - Eli Lilly (LLY.N), opens new tab is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada, the Globe and Mail reported on ...